iTeos shares jump by 40%. GSK and iTeos collaboration for Belrestotug looks like a worthy wait. Hopes to ward off the negative sentiments around the volatile TIGIT space?
In the ever-evolving landscape of cancer immunotherapy, the pursuit of effective treatment strategies continues to drive innovation and investment. Following the success of PD-(L) 1, TIGIT emerged as one of the most promising and prospective targets, garnering significant interest and investment from key players in the field. Interest in TIGIT has exploded over the past 3 years, with Merck and Roche quickly expanding their clinical development programs, while Bristol Myers and Gilead/Arcus strikin...
